Stock Price & Analysis

Buy AstraZeneca (AZN) stock as its strategic investments in R&D and expansion in China position it well for growth. The stock's technical indicators and positive analyst sentiment further support this decision.

AstraZeneca (AZN) stock is predicted to reach $85 by the end of 2025, driven by strong revenue growth, a robust pipeline, and positive analyst sentiment. The company's focus on oncology and immunology, along with successful product launches, supports this bullish outlook.

The S1 support level for AZN Stock is $72.31 ,The R1 resistant level for AZN Stock is $76.29.

As of the end of day on 2025-04-01, the price of AZN Stock was $72.93.

The target price for AZN Stock according to analyst rating is 92.93, with the highest price target at 97.00 and the lowest at 88.00. Analysts have a Strong Buy rating on AZN Stock overall.

The market cap of AZN is $112.6B.

Analysis and Insights

AstraZeneca (AZN) appears to be slightly overvalued based on current market conditions and fundamental analysis.

Valuation Metrics:

• P/E Ratio: AZN's P/E ratio of 33.85 is higher than the industry average, indicating a premium valuation compared to its earnings.
• Forward P/E: The forward P/E of 28.12 suggests expectations of future growth, but it remains elevated.
• PEG Ratio: A PEG ratio of 1.27 indicates the stock is fairly valued relative to its growth prospects.

Recent Investments and Risks:

• China Expansion: AZN's $2.5 billion investment in a Beijing R&D center reflects strategic growth efforts.
• UK Regulatory Risks: High levies on pharmaceutical companies in the UK could hinder investment and profitability.

Technical Analysis:

• Price Trends: AZN is trading at $74.97, below its 52-week high of $78.26 but above its low of $72.47.
• RSI: The RSI of 33.85 indicates oversold conditions, suggesting potential short-term upside.
• MACD: The MACD is slightly positive, but the signal line is below the MACD line, indicating weak momentum.
• Fibonacci Levels: Support at $74.68 and resistance at $77.42 are key levels to watch.

Analyst Sentiment:

• Consensus Rating: A moderate buy rating with a target price of $76.05 suggests cautious optimism.

Conclusion:

While AZN's strategic investments and pipeline are positives, the high valuation and UK regulatory risks pose concerns. Investors should exercise caution and consider waiting for a clearer risk picture or a more favorable entry point.

AstraZeneca PLC is a science-led biopharmaceutical company. It discovers, develops, and commercializes prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal and metabolism, respiratory and immunology and vaccines and immune therapies. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its biopharmaceuticals products include Farxiga, Crestor, Breztri and others. Its investigational vaccine candidate IVX-A12, which targets both respiratory syncytial virus and human metapneumovirus. Its oncology candidate includes FPI-2265 targeting prostate specific membrane antigen for metastatic castration resistant prostate cancer, which is in a Phase II trial. It also discovers, develops, and manufactures T-cell receptor therapies. Its Eneboparatide is an investigational therapeutic peptide.

AstraZeneca (AZN) stock is predicted to reach $120 by 2030, driven by strong R&D investments and expanding market presence. The company's $2.5 billion investment in a Beijing R&D hub and robust Q4 2024 earnings growth position it for sustained expansion.

AZN has a total of 89900 employees.